Department of Internal Neurology, The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People's Hospital), Ganzhou, Jiangxi, 341000, China.
Department of Medical Oncology, The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People's Hospital), Ganzhou, Jiangxi, 341000, China.
Sci Rep. 2018 Jan 23;8(1):1439. doi: 10.1038/s41598-018-19949-z.
The relationship between O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and clinicopathological characteristics of non-small-cell lung carcinoma (NSCLC) has remained controversial and unclear. Therefore, in this study we have undertaken a systematic review and meta-analysis of relevant studies to quantitatively investigate this association. We identified 30 eligible studies investigating 2714 NSCLC patients. The relationship between MGMT hypermethylation and NSCLC was identified based on 20 studies, including 1539 NSCLC patient tissue and 1052 normal and adjacent tissue samples (OR = 4.60, 95% CI = 3.466.11, p < 0.00001). MGMT methylation varied with ethnicity (caucasian: OR = 4.56, 95% CI = 2.637.92, p < 0.00001; asian: OR = 5.18, 95% CI = 2.0313.22, p = 0.0006) and control style (autologous: OR = 4.44, 95% CI = 3.325.92, p < 0.00001; heterogeneous: OR = 9.05, 95% CI = 1.7945.71, p = 0.008). In addition, MGMT methylation was observed to be specifically associated with NSCLC clinical stage, and not with age, sex, smoking, pathological types, and differentiation status. Also MGMT methylation did not impact NSCLC patients survival (HR = 1.32, 95% CI = 0.772.28, p = 0.31). Our study provided clear evidence about the association of MGMT hypermethylation with increased risk of NSCLC.
O-6-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）启动子甲基化与非小细胞肺癌（NSCLC）的临床病理特征之间的关系一直存在争议且尚未明确。因此，在本研究中，我们对相关研究进行了系统回顾和荟萃分析，以定量研究这种相关性。我们确定了 30 项研究，共纳入了 2714 例 NSCLC 患者。通过 20 项研究确定了 MGMT 过度甲基化与 NSCLC 之间的关系，其中包括 1539 例 NSCLC 患者组织和 1052 例正常和相邻组织样本（OR=4.60，95%CI=3.466.11，p<0.00001）。MGMT 甲基化与种族（白种人：OR=4.56，95%CI=2.637.92，p<0.00001；亚洲人：OR=5.18，95%CI=2.0313.22，p=0.0006）和对照方式（自体：OR=4.44，95%CI=3.325.92，p<0.00001；异质性：OR=9.05，95%CI=1.7945.71，p=0.008）有关。此外，MGMT 甲基化与 NSCLC 临床分期有关，而与年龄、性别、吸烟、病理类型和分化状态无关。此外，MGMT 甲基化并不影响 NSCLC 患者的生存（HR=1.32，95%CI=0.772.28，p=0.31）。我们的研究提供了明确的证据，表明 MGMT 过度甲基化与 NSCLC 风险增加有关。
